Back to News
Market Impact: 0.2
Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH
Source: Nasdaq
Healthcare & BiotechMarket Technicals & FlowsRegulation & Legislation
Pharvaris N.V. was among biotech stocks reaching a 52-week high on September 8, 2026. The article attributes the biotech-sector strength to clinical developments and regulatory milestones, although the provided text does not include specific trial results, regulatory decisions, or share-price changes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PHVS0.45
More News
- Asia stocks slip on tech losses with oil surge, yields in focus
- Asian stocks wilt as Brent holds above $100, yields near 2023 peak
- Stock futures are little changed as traders brace for wholesale inflation report: Live updates
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights